Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Common Equity (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Common Equity for 7 consecutive years, with $181.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 40.41% to $181.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $181.2 million, a 40.41% decrease, with the full-year FY2025 number at $181.2 million, down 40.41% from a year prior.
  • Common Equity was $181.2 million for Q4 2025 at Pliant Therapeutics, down from $200.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $561.9 million in Q1 2023 to a low of $147.8 million in Q2 2022.
  • A 5-year average of $315.5 million and a median of $284.1 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 507.98% in 2021, then tumbled 43.95% in 2025.
  • Pliant Therapeutics' Common Equity stood at $199.1 million in 2021, then surged by 57.41% to $313.3 million in 2022, then soared by 51.14% to $473.6 million in 2023, then crashed by 35.79% to $304.1 million in 2024, then plummeted by 40.41% to $181.2 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Common Equity are $181.2 million (Q4 2025), $200.3 million (Q3 2025), and $220.1 million (Q2 2025).